{"filings":[{"id":705279,"accession_number":"0001411690-26-000033","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2026-05-28T12:00:17+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bionano retires all $20M senior secured convertible debentures, eliminating secured debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Retired $20M in senior secured convertible debentures using cash on hand on May 26, 2026.","All liens on company's assets released and restrictive covenants extinguished.","Company now has no outstanding secured debt obligations, providing greater financial flexibility.","Debentures originally issued in May 2024; retirement completes the debt restructuring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-05-28","daily_digest_url":"/daily/2026-05-28","daily_digest_rank":8},{"id":443438,"accession_number":"0001411690-26-000030","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2026-05-14T20:29:23+00:00","items":["5.07"],"status":"ready","headline":"Bionano Genomics stockholders elect Luderer and Vuori as directors; pay vote and auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Albert Luderer (847,601 for) and Kristiina Vuori (867,474 for) as Class II directors for three-year terms.","Advisory vote on named executive officer compensation passed with 697,999 for, 216,553 against, 76,839 abstentions.","Ratification of BDO USA as independent auditor for fiscal 2026 passed with 3,770,715 votes for, 206,541 against.","Quorum was 38.1% of 11,091,615 shares outstanding (4,225,995 shares present).","Broker non-votes totaled 3,234,604 on director elections and compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":67885,"accession_number":"0001411690-26-000027","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2026-05-13T20:03:04+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Q1 revenue $6.7M (+4% YoY); gross margin 49%; positive coding updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $6.7M (+4% vs $6.5M Q1 2025); consumables revenue $3.9M (+20%).","Gross margin improved to 49% from 46% YoY; sold 8,178 nanochannel flow cells (+17%).","Operating expenses cut 2% to $11.1M; adjusted op. expense +7% to $9.1M.","New CPT code 81354 for OGM in constitutional genetics effective Jan 1, 2026, priced above microarray codes.","Final CLFS shows 47% payment increase for CPT 81195 (OGM in hematologic malignancy) to $1,853.22."],"consensus_eps_estimate":-0.969,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":6687000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92709,"accession_number":"0001411690-26-000019","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Bionano Genomics CEO Erik Holmlin terminated; Chairman Al Luderer named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Erik Holmlin terminated effective May 5, 2026; will serve as advisor under consulting agreement.","Board appoints Chairman Albert Luderer as interim CEO and interim principal financial officer.","Luderer receives $600k base salary, up to $400k bonus, and $4k/month housing/travel stipend.","Chris Twomey appointed Lead Independent Director to support governance during transition.","Company will immediately commence search for a permanent CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103759,"accession_number":"0001411690-26-000006","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Q4 2025 revenue $8.0M (-3% YoY); FY revenue $28.5M (-7%)","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 2025 revenue $8.0M vs $8.2M Q4 2024; consumables/software revenue down 1%.","Full-year 2025 revenue $28.5M vs $30.8M FY2024; consumables/software up 7%.","Q4 gross margin 43% (42% prior); non-GAAP gross margin also 43%.","Operating expenses reduced 22% to $11.9M in Q4; installed base 387 systems (+4%).","Company provided 2026 revenue outlook (specific figures not available in excerpt)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103758,"accession_number":"0001140361-26-000904","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano reports preliminary Q4/FY 2025 revenue down 2-8% YoY; cash $29.6M","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Total Q4 revenue $7.8-8.0M, down 2-4% YoY; full-year $28.4-28.6M, down 7-8%.","Installed 9 new OGM systems in Q4, 32 in FY; installed base at 387 systems at year-end.","Cash, equivalents and restricted investments $29.6M as of Dec 31, 2025 ($10.3M restricted).","Nanochannel array flowcells sold: 7,554 in Q4, 30,171 for full year 2025.","Preliminary unaudited results; subject to change after year-end close and audit."],"consensus_eps_estimate":-1.428,"consensus_eps_actual":-4.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":28508000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120017,"accession_number":"0001411690-25-000092","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Q3 revenue $7.4M (+21% YoY); raises FY 2025 OGM install guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $7.4M, up 21% from $6.1M in Q3 2024; consumables/software revenue +15%.","GAAP gross margin 46% vs (139)% a year ago; non-GAAP gross margin 46% vs 26%.","Operating expenses cut 66% to $11.9M; cash and investments $31.8M at quarter-end.","Raised FY 2025 OGM system install guidance to >25 units (prior 20-25).","Reiterated FY 2025 revenue guidance $26-30M; Q4 2025 revenue guided $7.5-7.9M."],"consensus_eps_estimate":-1.9482,"consensus_eps_actual":-4.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":20557000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136579,"accession_number":"0001140361-25-035286","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Bionano Genomics closes $10M public offering of 5M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $10M from sale of 5M shares and Series E/F warrants to purchase up to 10M shares.","Net proceeds approximately $9.0M after placement agent fees and offering expenses.","Warrants exercisable at $2.00 per share; Series E expire in 5 years, Series F in 18 months.","Proceeds to be used for working capital and general corporate purposes.","Offering closed on September 17, 2025; H.C. Wainwright acted as exclusive placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136578,"accession_number":"0001411690-25-000082","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Q2 2025 revenue $6.7M (-13% YoY); gross margin 52% vs 33%; flowcell sales +17%","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Total revenue $6.7M (-13% YoY); prior year included $0.7M discontinued clinical services; adjusted consumables/software/services up 11%.","Gross margin 52% (non-GAAP 52%) vs 33% a year ago; operating expenses cut 42% to $11.3M.","Sold 7,233 flowcells (+17% YoY); installed OGM base 378 systems (+4% YoY).","Full-year 2025 revenue reaffirmed $26-30M; Q3 2025 guidance $6.7-7.2M; cash runway into Q1 2026."],"consensus_eps_estimate":-2.4633,"consensus_eps_actual":-3.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":13190000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153767,"accession_number":"0001411690-25-000077","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K/A","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bionano Genomics corrects vote counts for Proposals 3 and 4; results unchanged","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrected Broker Non-Votes for Proposal 3 from 769,744 to 0; no impact on ratification of BDO USA as auditor.","Corrected Broker Non-Votes for Proposal 4 from 0 to 769,944; vote outcome unchanged.","Corrected Votes For on Proposal 4 from 369,176 to 396,176; still approved.","All shareholder vote outcomes remain the same per the original June 13, 2025 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153769,"accession_number":"0001411690-25-000073","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"BNGO holds annual meeting, re-elects directors, approves share issuance, appoints Vuori to audit committee","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Kristiina Vuori appointed to Audit Committee effective June 10, 2025.","Holmlin and Barker elected as Class I directors with 377,358 and 382,707 votes for, respectively.","Advisory vote on executive compensation approved with 375,470 for, 328,513 against, showing notable dissent.","Ratification of BDO USA as auditor approved (1,304,265 for vs 99,528 against).","Issuance of up to 661,374 shares upon exercise of purchase warrants approved (369,176 for, 311,661 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153768,"accession_number":"0001411690-25-000045","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Q1 revenue $6.5M, down 26% YoY; FY2025 guidance $26-30M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $6.5M vs $8.8M YoY, down 26%; GAAP gross margin improved to 46% from 32%.","Flowcell sales 6,994 units (-15% YoY); to routine customers up 1% after adjusting for new adds.","GAAP operating expense $11.4M, down 66% YoY from cost cuts and restructuring.","Cash, equivalents and investments $29.2M; cash runway extended into Q1 2026.","FY2025 revenue guidance updated to $26-30M; Q2 revenue expected $6.3-6.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":6457000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172459,"accession_number":"0001411690-25-000036","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Genomics Q4 revenue down 24% YoY to $8.2M; full-year revenue $30.8M, down 15%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $8.2M vs $10.8M in Q4 2023, decline driven by discontinued clinical services; core product revenue 1% higher for full year.","GAAP gross margin improved to 42% from 23% YoY; GAAP operating expense cut to $15.4M from $27.4M.","Full-year product revenue $27.0M (+1% YoY) with consumables +14% and software +11%; instruments down ~$2M.","Installed OGM systems 371 (+14% YoY); flowcell sales 30,307 (+15% YoY); 336 OGM publications in 2024.","Cash & securities $20.9M at year-end (incl. $11.4M restricted); raised $10M in Jan 2025 offering; modified debentures to reduce payments."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":6457000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172458,"accession_number":"0001140361-25-005427","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bionano Genomics enters new $75M ATM sales agreement with H.C. Wainwright, replacing Cowen facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated prior Cowen sales agreement effective Feb 14, 2025; suspended offering Feb 4.","New ATM with H.C. Wainwright allows sale of up to $75M of common stock at market prices.","Wainwright receives 3.0% commission on gross proceeds from each sale.","Shares sold on Nasdaq through at-the-market offerings; company may suspend at any time.","Registration statement on Form S-3 effective May 10, 2023, covering the new facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172457,"accession_number":"0001140361-25-003762","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Bionano Genomics terminates $200M ATM equity facility with Cowen, effective Feb 14, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Sales Agreement with Cowen and Company effective Feb 14, 2025.","Agreement allowed sale of up to $200M in common stock via ATM program.","Company provided notice on Feb 4, 2025; no reason disclosed for termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172456,"accession_number":"0001411690-25-000008","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Bionano Genomics effects 1-for-60 reverse stock split effective Jan 24, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio 1:60, effective 5:00 p.m. ET on January 24, 2025.","Common stock begins trading split-adjusted on Nasdaq Capital Market under BNGO on Jan 27.","No fractional shares issued; stockholders entitled to fractional shares receive cash in lieu.","Proportionate adjustments to stock options, RSUs, warrants, and convertible debentures exercise prices and share counts.","New CUSIP number for common stock post-split: 09075F404."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172455,"accession_number":"0001411690-25-000005","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bionano Genomics stockholders approve reverse stock split (1:25-1:75) and warrant share issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At Jan 15 special meeting, stockholders approved issuance of up to 19,762,226 shares upon exercise of Series C/D warrants.","Proposal 2 approved reverse stock split at ratio between 1-for-25 and 1-for-75, with exact ratio to be set by Board.","Approvals required for Nasdaq listing compliance and to maintain stock price above minimum bid.","Votes: Proposal 1 – 7.1M for, 3.3M against, 6.7M abstain, 25.3M broker non-votes.","Votes: Proposal 2 – 29.0M for, 12.8M against, 0.6M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172454,"accession_number":"0001411690-25-000003","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano reports preliminary Q4 rev $7.9-8.1M (down ~25% YoY); FY rev $30.5-30.7M (down ~15%)","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary Q4 2024 revenue $7.9-8.1M, down ~25% from Q4 2023 due to discontinued clinical service products.","Full year 2024 revenue $30.5-30.7M, down ~15% from FY2023; excluding discontinued services, core revenue ~$29M, roughly flat.","OGM installed base 371 units at year-end, up 14% from 326 at end of 2023; flowcell sales 8,058, up 1% YoY.","Cash, equivalents and AFS securities $20.9M as of Dec 31, 2024; raised $10M gross via registered direct offering in Jan 2025.","Annualized operating costs reduced by ~$100M since May 2023; senior secured convertible debenture terms modified to lower monthly payments."],"consensus_eps_estimate":null,"consensus_eps_actual":-88.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":30776000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172453,"accession_number":"0001140361-25-000296","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Bionano Genomics raises $10M in registered direct offering of ~39.7M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate gross proceeds of ~$10M from sale of 22.9M common shares and 16.78M pre-funded warrants at $0.252/unit.","Each share/pre-funded warrant includes a purchase warrant exercisable at $0.252; warrants require stockholder approval, expire in 5 years.","Closing expected on January 6, 2025; H.C. Wainwright serves as placement agent with 6% cash fee.","Net proceeds to be used for working capital, R&D, debt repayment or redemption, and capital expenditures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172452,"accession_number":"0001140361-25-000132","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Bionano Genomics amends convertible debentures, reduces near-term payments, conversion price to $0.27","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment defers December 2024 redemption; monthly payments cut from $1M to $500k for Jan-Jul 2025, then rise to $1.375M from Aug 2025.","Conversion price reduced from $2.00 to $0.27; $15M principal convertible into 55.6M shares; 45.6M unregistered.","Company issued 5M shares as consideration; forbears from redemption notices until July 31, 2025.","Company to file registration statement for resale of shares by Jan 7, 2025.","Canaccord Genuity acted as exclusive financial advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189455,"accession_number":"0001411690-24-000066","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bionano Genomics stockholders approve issuance of up to 35M shares upon warrant exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vote passed: 22.9M for, 6.2M against, 1.4M abstentions, no broker non-votes.","Approval covers Series A and B warrants from July 4, 2024 private placement to institutional investors.","Issuance required for Nasdaq Listing Rule 5635(d) compliance; warrants were already outstanding.","Potential dilutive impact: up to 35M shares vs. ~86M outstanding as of August 12, 2024 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189454,"accession_number":"0001411690-24-000060","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Q3 revenue $6.1M (-35% YoY); GAAP gross margin -139% on $9.8M impairment; cash burn down","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.1M (-35% YoY); core product/software sales $6.6M offset by $0.5M receivable write-down from discontinued clinical services.","GAAP gross margin (139)% vs 30% YoY due to $9.8M impairment/disposal of reagent rentals and inventory; non-GAAP margin 26%.","GAAP operating expense $35.5M; non-GAAP $16.1M (-49% YoY). Cash, securities & restricted cash $23.4M as of Sept 30.","Installed base 368 OGM systems (+22% YoY); 7,835 flowcells sold (+27% YoY). Raised $10M upfront from registered direct offering & warrants Q3, plus $3M post-Q3.","Special meeting adjourned for lack of quorum; reconvenes Nov 27. CPT code for OGM in blood cancers expected 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":22613000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189453,"accession_number":"0001140361-24-044715","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Bionano Genomics raises ~$3M in registered direct offering of 9.9M shares and warrants at $0.3039/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 9,881,113 shares of common stock and Series C/D warrants to purchase up to 9,881,113 shares each at $0.3039 per share.","Gross proceeds of $3M from offering, with potential additional $6M if warrants fully exercised on cash basis.","Closing expected on October 31, 2024; H.C. Wainwright acted as exclusive placement agent with 6% cash fee.","Net proceeds to be used for working capital, R&D, repayment or redemption of existing indebtedness, and capex.","Warrants exercisable only after stockholder approval; Series C expires in 5 years, Series D in 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189452,"accession_number":"0001140361-24-043244","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano lowers Q3 revenue guidance to $6.5-6.8M from $7.9-8.9M; cash $23.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q3 revenue $6.5-6.8M, down from prior guidance of $7.9-8.9M.","Cash and restricted cash ~$23.3M as of Sep 30; $11.4M restricted.","Revenue miss driven by strategic shift away from new OGM system placements and sector headwinds.","Potential material impairments and charges pending completion of end-of-period review."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":22613000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205962,"accession_number":"0001140361-24-040508","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["2.05","5.02","7.01","9.01"],"status":"ready","headline":"Bionano cuts workforce 45%, lowers revenue guidance to $32-36M, CFO departs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction of ~84 employees (45% of workforce); expects $25-30M annual cost savings starting Q4 2024.","Revenue guidance reduced to $32-36M from $36-40M due to fewer OGM instrument placements.","CFO Gülsen Kama leaving effective Sep 18; CEO Erik Holmlin appointed principal financial officer.","Restructuring charges estimated at $0.5-1.0M, substantially complete by Oct 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205961,"accession_number":"0001411690-24-000046","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Q2 revenue $7.8M (-10% YoY); FY2024 guidance $36-40M; retires $15.3M notes","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $7.8M, down 10% YoY; GAAP gross margin 33% vs 27% in Q2 2023.","GAAP operating expense $19.6M, down 53% YoY; non-GAAP $18.8M, down 46%.","Cash and securities $30.3M as of June 30, with $11.4M restricted; $20M in debentures outstanding.","Retired $15.3M convertible notes for $17.6M redemption plus $2.2M fee, funded by $18M private placement of senior secured convertible debentures.","Guides full year 2024 revenue $36-40M; Q3 2024 revenue expected $7.9-8.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":16540000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205960,"accession_number":"0001411690-24-000044","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Bionano Genomics receives Nasdaq notice for bid price below $1.00; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Bionano on July 12, 2024 that its stock closed below $1.00 for 30 consecutive trading days.","Company has 180 calendar days to regain compliance; closing bid price must be at least $1.00 for 10 consecutive business days.","If non-compliance persists, Bionano may seek an additional 180-day period if it meets other listing standards.","Stock continues trading on Nasdaq Capital Market under symbol BNGO; delisting possible if not cured.","Bionano intends to monitor the bid price and may consider options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205959,"accession_number":"0001140361-24-032559","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Bionano raises $10M upfront via registered direct offering; adds $20M potential from milestone warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["17.5M shares/equivalents sold at $0.571/share for gross proceeds of ~$10M.","Concurrent private placement includes Series A & B warrants exercisable at $0.571/share, offering up to $20M additional.","Series A warrants expire 24 months post-stockholder approval or 60 days after MolDX coverage for optical genome mapping.","Series B warrants expire 5 years post-approval or 6 months after FDA clearance for optical genome mapping system.","Net proceeds earmarked for working capital, R&D, debt repayment, and capex; closing expected July 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222977,"accession_number":"0001411690-24-000040","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bionano Genomics stockholders elect three Class III directors, approve say-on-pay, ratify auditor at 2024 meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Christopher Twomey, Yvonne Linney, and Aleksander Rajkovic as Class III directors until 2027.","Advisory vote on executive compensation approved: 9,508,999 for, 1,771,611 against, 642,388 abstentions.","Ratification of BDO USA as independent auditor for FY 2024 approved: 26,950,772 for, 2,788,563 against, 308,349 abstentions.","Approximately 44.94% of outstanding shares (30,047,684) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222976,"accession_number":"0001140361-24-027553","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Bionano raises $18M via convertible debt, retires High Trail Note, warns of going concern","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $20M principal senior secured convertible debentures (11% interest, due 2026) plus 2.25M shares for $18M gross proceeds.","Used ~$17.6M to redeem High Trail Note (outstanding $15.337M at 115% redemption, plus $2.19M retirement fee); Note cancelled.","Debentures convertible at $2.00/share; Company must maintain $11M blocked account; monthly redemption up to $1M allowed.","Cash runway only into Q4 2024; substantial doubt about going concern exists; board formed strategy committee for alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}